DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

MS Contin (Morphine Sulfate) - Summary

 
 



WARNING:

MS CONTIN contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.

Morphine can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing MS CONTIN in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

MS CONTIN Tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

MS CONTIN Tablets are NOT intended for use as a prn analgesic.

MS CONTIN 100 and 200 mg Tablets ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. These tablet strengths may cause fatal respiratory depression when administered to patients not previously exposed to opioids.

MS CONTIN TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, DISSOLVED, OR CRUSHED. TAKING BROKEN, CHEWED, DISSOLVED, OR CRUSHED MS CONTIN TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.

 

MS CONTIN SUMMARY

MS CONTIN (morphine sulfate) is an opioid analgesic.

MS CONTIN is a controlled-release oral morphine formulation indicated for the relief of moderate to severe pain. It is intended for use in patients who require repeated dosing with potent opioid analgesics over periods of more than a few days.

The MS CONTIN 200 mg tablet strength is a high dose, controlled-release, oral morphine formulation indicated for the relief of pain in opioid-tolerant patients only.


See all MS Contin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to MS Contin (Morphine)

'Light was as rewarding as morphine' in mice with new opioid receptors
Source: Pain / Anesthetics News From Medical News Today [2015.05.04]
A light-sensitive protein from the retina of the eye, melded to an opioid brain receptor, has induced reward-stimulation in mice - raising early research hopes for safer drugs.

Morphine After Tonsillectomy Tied to Breathing Problems in Study
Source: MedicineNet Tonsillectomy Specialty [2015.01.26]
Title: Morphine After Tonsillectomy Tied to Breathing Problems in Study
Category: Health News
Created: 1/26/2015 12:00:00 AM
Last Editorial Review: 1/26/2015 12:00:00 AM

Exercise Stimulates Pain Modulation in Fibromyalgia
Source: Medscape Medical News Headlines [2015.05.22]
Exercise activates areas of the brain associated with pain modulation, suggesting it could be an effective treatment for fibromyalgia.
Medscape Medical News

Subconscious learning shapes pain responses
Source: Pain / Anesthetics News From Medical News Today [2015.05.22]
In a new study led from Sweden's Karolinska Institutet, researchers report that people can be conditioned to associate images with particular pain responses - such as improved tolerance to pain ...

More Babies Born to Mothers Addicted to Pain Meds
Source: MedicineNet Pregnancy Drug Dangers Specialty [2015.05.22]
Title: More Babies Born to Mothers Addicted to Pain Meds
Category: Health News
Created: 5/22/2015 12:00:00 AM
Last Editorial Review: 5/22/2015 12:00:00 AM

more news >>

Published Studies Related to MS Contin (Morphine)

Evaluation of a single-dose, extended-release epidural morphine formulation for pain control after lumbar spine surgery. [2014]
DepoDur, an extended-release epidural morphine, has been used effectively for postoperative pain control following many orthopaedic and general surgery procedures and has provided prolonged analgesia when compared with Duramorph. The goal of this article was to compare the safety and analgesic efficacy of DepoDur versus Duramorph after lumbar spine surgery...

Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. [2014]
effects on platelets... CONCLUSIONS: Morphine delays clopidogrel absorption, decreases plasma levels of

The postoperative analgesic effect of morphine and paracetamol in the patients undergoing laparotomy, using PCA method. [2013]
CONCLUSION: Morphine seems to be more effective at 2 and 4 hours, but after 4

Comparison of the efficacy and safety of dual-opioid treatment with morphine plus oxycodone versus oxycodone/acetaminophen for moderate to severe acute pain after total knee arthroplasty. [2013]
oxycodone/acetaminophen and fixed low-dose morphine/oxycodone... CONCLUSIONS: Flexible dose morphine/oxycodone was superior to low-dose

Effect of morphine on lower urinary tract discomfort after transurethral resection of prostate under general anesthesia: a randomised clinical study. [2013]
TURP-related LUT discomfort symptoms... CONCLUSION: Based on these results, we conclude that morphine effectively reduces

more studies >>

Clinical Trials Related to MS Contin (Morphine)

Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction [Completed]
This study involves approximately 200 patients designed to evaluate the efficacy and safety of intranasal (IN) morphine 7. 5 mg and 15 mg, intravenous morphine (IV) 7. 5 mg, immediate release oral (PO) morphine 60 mg or placebo in patients with acute postsurgical pain following third molar extraction.

Intrathecal Morphine in Knee Arthroplasty [Completed]
This study is designed to explore the efficacy lower doses of intra-spinal morphine for pain relief and side effect profiles of same in the setting of Total Knee Replacement. We hypothesized that a dose greater than that used in Total Hip Replacement was needed and wished to find a dose which was effective but had a low side effect profile.

Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery [Completed]
Study designed to evaluate the efficacy and safety of Intranasal (IN) Morphine Nasal Spray (MNS075) 3. 75 mg, 7. 5 mg, 15 mg, and 30 mg, intravenous (IV) morphine 7. 5 mg, or IN placebo in patients with moderate to severe post-surgical pain following orthopedic surgery. After initial dosing, up to six (6) doses of IN MNS075 7. 5 mg or 15 mg for up to twenty-four (24) hours will be evaluated. The rescue dose remained the same for each.

A Study of Kadian NT in Subjects With Pain Due to Osteoarthritis of the Hip or Knee [Completed]
The purpose of this study is to evaluate the efficacy of Kadian NT compared with placebo for treating moderate to severe chronic pain over a 12 week period.

INFUSE Morphine Study [Completed]
Double-blind study comparing the pharmacokinetics, safety and tolerability of morphine administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX) and intravenously conducted in patients in a hospice care setting or through a palliative care medicine setting. In this within-patient controlled study, each eligible study patient receives a single injection by each of the three methods of morphine administration, sequentially on three consecutive days, according to the order specified by a randomization schedule.

Each of the three injections consists of 5 mg of morphine (1. 0 mL of 5 mg/mL solution). The HYLENEX injection will be 1 mL of 150 units. Although the IV administration will not be blinded, the two SC injections will be double-blinded, using the same volume of normal saline (0. 9% sodium chloride) placebo (1. 0 mL) as HYLENEX.

more trials >>

Reports of Suspected MS Contin (Morphine) Side Effects

Pain (16)Confusional State (15)Anaemia (15)Diarrhoea (15)Nausea (13)Weight Decreased (12)Drug Ineffective (12)Renal Failure Acute (12)Delirium (12)Drug Abuse (11)more >>


Page last updated: 2015-05-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015